Literature DB >> 26346942

Elevated Troponin I in the Absence of Coronary Artery Disease: A Case Report With Review of Literature.

Sabrina Arshed1, Hong Xiu Luo1, Shoaib Zafar1, Kalyani Regeti1, Nilma Malik1, Mahmood Alam1, Abdalla Yousif1.   

Abstract

Cardiac troponins are the most sensitive and specific markers of myocardial injury. In fact, the Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction (MI) states that troponins are the preferred cardiac marker for detecting myocardial injury. For the aforementioned reasons, troponin levels are routinely ordered for patients presenting to the emergency department with chest pain, dyspnea, syncope, or any other possible presentations of MI. While troponin levels do reflect the extent of myocardial damage, they do not necessarily indicate myocardial ischemia in a subset of patients. Elevated troponin levels can be due to a wide array of mechanisms in the absence of myocardial ischemia and injury. Thus, relying solely on troponin levels, in the presence of a normal electrocardiogram (ECG), to diagnose myocardial ischemia can lead to unnecessary and expensive invasive testing. It is therefore important for the clinician to keep in mind the varying causes of troponin elevations in order to provide the highest value care to the patient. We present a case and review of literature regarding patients who present with elevated troponin levels in the absence of any coronary artery disease.

Entities:  

Keywords:  Cardiac biomarkers; Coronary artery disease; Idiopathic; Myocardial injury; NSTEMI; Troponin

Year:  2015        PMID: 26346942      PMCID: PMC4554225          DOI: 10.14740/jocmr2280w

Source DB:  PubMed          Journal:  J Clin Med Res        ISSN: 1918-3003


Introduction

Cardiac enzymes coupled with electrocardiogram (ECG) and a clinical picture of chest pain have traditionally been the trifecta used in the diagnosis of acute myocardial infarction (MI). However, it is becoming increasingly more frequent to see patients with little to no symptoms and/or ECG changes, requiring more reliance upon cardiac enzymes as the tool of choice to diagnose non-ST elevation myocardial infarction (NSTEMI) [1, 2]. It is important to note that although MI may be the most common cause of elevated cardiac enzymes, more specifically troponin, it is certainly not the only cause [1, 2]. The elevated troponins in the absence of myocardial ischemia are rare; however, it can be seen in conditions such as myocarditis, pulmonary embolism, acute heart failure, sepsis and septic shock, hypovolemia, renal failure, atrial fibrillation and cardiac contusion [2, 3]. This paper discusses a case of a patient with an unexplained elevation of troponin I (cTnI) in the absence of coronary artery disease and other relatively common non-cardiac etiologies. The numerous causes of non-coronary-related cTnI elevations are discussed.

Case Report

This is a case of a 57-year-old female with a past medical history of hypertension, dyslipidemia, depression, osteoarthritis and NSTEMI 2 years prior to admission, who recently traveled from Florida to New Jersey 3 weeks prior to admission, and had received a corticosteroid injection into her knee for the treatment of osteoarthritis earlier the day of admission. This patient came to the emergency department complaining of palpitations and lightheadedness. She denied any shortness of breath, chest pain, diaphoresis or nausea and/or vomiting. She denied any sick contacts, fever, chills, cough or any recent flu-like symptoms. On further evaluation of this patient, ECG showed sinus tachycardia with HR of 102/min without any ST-T deviation, and chest X-ray showed no acute process. NT Pro-BNP was found to be 61.75 pg/mL (significant if > 450 pg/mL in those < 50 years of age, > 900 pg/mL in those 50 - 75 years of age, > 1,800 pg/mL in those > 75 years of age, if < 300 heart failure is highly unlikely) and a D-dimer of 0.23 μg/mL (normal value < 0.50 μg/mL); further laboratory tests including TSH and rheumatoid factor were within normal limits, except for a cTnI of 4.01 ng/mL (normal value 0 - 0.1 ng/mL). CT angiogram of the chest revealed no pulmonary embolism. An echocardiogram was done to assess the cardiac function of the patient and revealed a left ventricle with normal structure and function, no wall-motion abnormalities, no dilatation of the ventricle and an ejection fraction > 55%, without any evidence of pulmonary hypertension, pericardial effusion or aortic dissection. During this time, the patient’s cTnI continued to increase and peaked at 4.95 ng/mL (normal 0 - 0.1 ng/mL), and a cardiac catheterization was done, which showed normal coronary arteries without any evidence of coronary artery disease, no hypokinesis of the ventricular walls, no ballooning of the apex, and an intra-catheterization LVEF of 65%. It is interesting to note that this patient had a similar episode 2 years prior to this admission, which was her “NSTEMI”, where the patient’s presenting cTnI level was 2.26 ng/mL (normal 0 - 0.1 ng/mL), and again a full cardiac workup was done, including echocardiogram and cardiac catheterization, demonstrating normal cardiac function without any evidence of coronary artery disease, hypokinesis of the left ventricle, and no evidence of either systolic or diastolic left ventricular dysfunction by echocardiography. The patient remained stable and chest-pain free post cardiac catheterization and was discharged home shortly thereafter on lisinopril and aspirin. Curiously, both times the patient presented with elevated troponins, and she was discharged with elevated troponins and no definite diagnosis; however, we theorize that, given her history of depression, she may have been suffering from a milder apical-sparing variant of stress cardiomyopathy [4, 5].

Discussion

It is well known that cardiac enzymes, more specifically troponin, play a vital role in the diagnosis of acute coronary syndrome (ACS) and possible an MI, especially in the setting of ambiguous symptology or a non-specific ECG [1]. The release of troponins is predominantly controlled by irreversible myocyte damage and subsequent myocyte necrosis [6]; however, it is also known that cardiac troponins may be released into the blood stream in the absence of myocyte damage/necrosis [6]. There are three types of troponins that are released into the human blood stream, troponin C, troponin T (cTnT), and cTnI, each having a unique function [5]. However, cTnT and cTnI are expressed by cardiac muscle, and therefore the preferred troponin for measurement in myocardial injury [7]. In 2012, the Multinational Third Global MI Task Force updated the universal definition of MI to include the detection of cardiac biomarkers, one of which was elevated, preferably cTn [1]. Furthermore, patients must have at least one of five diagnostic criteria (Table 1) [1]. In addition to this new definition, the 2012 Task Force further evaluated and outlined the multiple mechanisms and/or types of MI (Table 2) [1].
Table 1

Additional Diagnostic Criteria (Apart From Cardiac Biomarkers) for the Diagnosis of Myocardial Infarction as per the 2012 Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction [1]

Symptoms of ischemia
New significant ST/T wave changes or new left bundle branch block on ECG
Pathological Q waves on ECG
Imaging evidence of myocardial wall motion abnormalities
Intra-catheterization or post-mortem evidence of coronary thrombus
Table 2

Types/Mechanism of Myocardial Infarction [1]

IPrimary myocardial ischemia, i.e. plaque rupture, thrombus formation
IISupply/demand ischemia, i.e. vasospasm, hypotension, arrhythmia, severe anemia
IIIInjury without ischemia, i.e. myocarditis, cardiac contusion
IVMultifactorial, i.e. heart failure, renal failure
The causes of myocardial damage range from coronary to non-coronary etiologies. Coronary causes of myocardial ischemia include ACS, cocaine use, coronary intervention, coronary artery spasm, severe hypertension, heart failure, acute aortic dissection and coronary artery vasculitis [2, 8]. However, for the purposes of this paper, the focus will be maintained on non-coronary causes of troponin elevations. There are multiple causes of elevated troponins in the absence of ACS, which Thygesen et al have conveniently grouped into three major categories: 1) myocardial damage due to myocardial ischemia [8]; 2) myocardial damage due to non-ischemic causes [8]; 3) idiopathic myocardial injury [8]. In the setting of non-coronary myocardial ischemia, common causes include sepsis and septic shock, hypoxia, hypo-perfusion, and pulmonary embolism (Table 3) [2, 8-12].
Table 3

Causes (Non-Acute Coronary Syndrome) of Elevated Troponin by System [9-12]

CardiovascularRespiratory
  Aortic dissection  Pulmonary embolism
  Arrhythmia  ARDS
  Heart failureInfectious/immune
  Endocarditis/myocarditis/pericarditis  Severe sepsis/septic shock
  LVH  Critical illness
  Infiltrative disease  TTP
  Stress cardiomyopathyGastrointestinal
Mechanical injury  Severe GI bleeding
  Blunt trauma/contusionCNS
  Cardiac surgery/angioplasty/ablation/cardioversion  Ischemic/hemorrhagic stroke
  CPR  Severe head trauma
Musculoskeletal/skinRenal
  Rhabdomyolysis  Chronic kidney disease
  Extensive burnsOther
Toxins/drugs  Strenuous exercise
  Cocaine
  Cardiotoxic chemotherapy
  Cyanide intoxication
  Carbon monoxide poisoning
  Amphetamines
  Scorpion/snake/box jellyfish venom
Many studies have shown the correlation of elevated troponins and the severity of sepsis, and found it to correlate with the degree of hypotension and the APACHE II score [10]. Many authors have hypothesized that severe sepsis may induce the release of myocardial depressive factors that lead to the breakdown of larger free troponin to smaller, lower-molecular-weight fragments, which, through increased membrane permeability, make their way into systemic circulation [11]. However, other theories suggest circulating cytokines as well as bacterial endotoxins cause a direct toxic effect on the myocardium, thus inducing the release of troponins [8]. However, ultimately, the exact mechanism remains unclear. While in pulmonary embolism, elevated troponins are associated with a worse prognosis. In a meta-analysis of multiple pulmonary embolism studies, patients with elevated troponin levels had greater than five times the mortality of those with normal troponin levels [11]. The mechanism behind troponin release in these patients is thought to be related to right ventricular dilatation and strain from increased pulmonary arterial resistance [10]. Additionally, there are multiple causes of elevated troponins and myocardial damage in which ischemia is not involved, and these include renal failure, infiltrative diseases, extreme exertion, cardiac contusion, extensive burns, acute pericarditis, myocarditis and stress cardiomyopathy, among many others (Table 3) [2, 8-11]. In acute pericarditis, elevations of troponins are believed to be related to acute inflammation and subsequent injury to the epicardial layer of the myocardium, thus causing a release of troponins [10]. Another common cause of troponin elevations in the absence of myocardial ischemia is renal failure; although, usually it is the cTnT, not usually cTnI, that is elevated [2-4, 9-11]. While the exact cause of this elevation of troponins in renal failure remains unknown, clinical outcomes have shown a worse prognosis for those patients with elevated troponin levels [10]. Stress cardiomyopathy, also known as Takotsubo cardiomyopathy or broken-heart syndrome, is caused by intense emotional or physical stress leading to rapidly occurring and severe reversible cardiac dysfunction, that typically occurs in women, especially post-menopausal women, accounting for approximately 1.05-2.2% of patients presenting with symptoms originally thought to be ACS [11, 13]. Although the exact mechanism remains unclear, it has been hypothesized that an exaggerated sympathetic stimulation may lead to a catecholamine-induced direct myocyte injury [11]. Furthermore, there seems to be a higher prevalence of stress cardiomyopathy among those suffering from anxiety and depression. Ziegelstein had reported that patients with psychiatric disorders may have a stronger catecholamine response to stress, as well as a decreased inhibition of catecholamine release [14, 15]. Apical sparing variants of stress cardiomyopathy have been reported in the past, in which the apical ballooning was thought to be transient, and therefore not visualized on imaging and diagnostic studies [4, 5, 13]. Other authors hypothesize that the hypokinesis/akinesis may be mid-ventricular, sparing the apex [4, 5, 16]. There have been multiple accounts of false-positive troponin elevations. Factors that may interfere with the cTnI include heterophilic antibodies, rheumatoid factor, fibrin clots and equipment malfunction (Table 4) [12, 17, 18].
Table 4

Causes of False-Positive Troponin Elevations [12, 17]

Heterophilic antibodies
Rheumatoid factor
Fibrin clots
Microparticles in the specimen
Immunocomplex formation
Analyzer malfunction
Heterophilic antibody induced troponin elevation has been reported by multiple studies with an incidence ranging from 0.17% to 40% [17, 18]. These heterophilic antibodies are usually acquired from iatrogenic and non-iatrogenic causes, including transfusion of blood products, vaccinations, autoimmune diseases and monoclonal antibody therapies, to name a few [19]. Rheumatoid factor elevations can cause falsely elevated cTnI levels as well. Krahn et al report that 5% of healthy patients have circulating rheumatoid factor, and an estimated 1% of patients with elevated cTnI levels have this elevation solely due to circulating rheumatoid factor [20, 21]. Furthermore, a recent study of patients with elevated cTnI levels with rheumatoid factor found that 11.5% were heterophilic false positive [20], and even after pre-treatment with heterophile blocking agents, approximately 50% of the false positives were not corrected [20]. Finally, idiopathic myocardial injury has been found to be a much more common phenomenon than previously believed. A study done by Bakshi et al, of 21 patients with elevated cTnI levels with normal coronary arteries on catheterization, was done to determine the etiology of the elevated troponin levels [20]. This study revealed the most common etiology was “no clear precipitating event” accounting for 47% of the patients [20]. Additional studies done by Assomull et al were done to determine the cause of elevated troponin levels in non-obstructive coronary artery disease, which revealed of their patient population, 50% had elevated troponin levels due to myocarditis [21], only 11.6% of these patients had elevated troponins due to an actual myocardial infarction [21], and 35% of these patients had elevated troponin levels with no clear diagnosis [21]. In our case, patient had elevated troponins on two separate occasions 2 years apart. However, defining our patient’s condition, and those with similar circumstances, as “idiopathic” simply means that there are unknown causes of troponin elevations which require further clinical and molecular investigation in the future. One of these possibilities may be that of a milder apical-sparing variant of stress cardiomyopathy, leading to myocyte injury without hypokinetic changes [4, 5].

Conclusion

While troponin plays a vital role in the diagnosis of NSTEMIs, it is imperative to keep in mind the multiple non-ischemic and non-cardiac causes and potential factors that may lead to elevations of troponin levels. The most common causes of elevated troponins can be divided into ACS and non-ACS causes. The most common ACS causes are comprised of STEMI, NSTEMI and unstable angina, generally speaking. While the non-ACS cause list is much longer, the most common causes include pulmonary embolism, sepsis and septic shock, pericarditis, myocarditis, cocaine use, aortic dissection, CKD and coronary artery spasm. Additionally, this patient had a negative rheumatoid factor, although heterophile antibody was never tested on this patient, it is unlikely that on two separate occasions this patients had false positive troponin elevations. Furthermore, elevation of her troponin levels 2 years apart makes equipment malfunction unlikely. In the case of our patient, we are hypothesizing that our patient, who is a middle-aged, post-menopausal female with a history of depression, may have suffered a milder apical-sparing variant of stress cardiomyopathy without any hypokinetic changes on diagnostic imaging [4, 5].
  18 in total

1.  Cardiac troponin elevations in patients without acute coronary syndrome.

Authors:  Christian W Hamm; Evangelos Giannitsis; Hugo A Katus
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

2.  Recommendations for the use of cardiac troponin measurement in acute cardiac care.

Authors:  Kristian Thygesen; Johannes Mair; Hugo Katus; Mario Plebani; Per Venge; Paul Collinson; Bertil Lindahl; Evangelos Giannitsis; Yonathan Hasin; Marcello Galvani; Marco Tubaro; Joseph S Alpert; Luigi M Biasucci; Wolfgang Koenig; Christian Mueller; Kurt Huber; Christian Hamm; Allan S Jaffe
Journal:  Eur Heart J       Date:  2010-08-03       Impact factor: 29.983

Review 3.  Differential diagnosis of elevated troponins.

Authors:  Susanne Korff; Hugo A Katus; Evangelos Giannitsis
Journal:  Heart       Date:  2006-07       Impact factor: 5.994

Review 4.  Stress cardiomyopathy: aetiology and management.

Authors:  Radhakrishnan Ramaraj
Journal:  Postgrad Med J       Date:  2007-08       Impact factor: 2.401

5.  Universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Harvey D White
Journal:  Eur Heart J       Date:  2007-10       Impact factor: 29.983

6.  The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries.

Authors:  Ravi G Assomull; Jonathan C Lyne; Niall Keenan; Ankur Gulati; Nicholas H Bunce; Simon W Davies; Dudley J Pennell; Sanjay K Prasad
Journal:  Eur Heart J       Date:  2007-05-03       Impact factor: 29.983

7.  Depression and tako-tsubo cardiomyopathy.

Authors:  Roy C Ziegelstein
Journal:  Am J Cardiol       Date:  2010-01-15       Impact factor: 2.778

8.  False increase of cardiac troponin I with heterophilic antibodies.

Authors:  T F Fitzmaurice; C Brown; N Rifai; A H Wu; K T Yeo
Journal:  Clin Chem       Date:  1998-10       Impact factor: 8.327

9.  Causes of elevated troponin I with a normal coronary angiogram.

Authors:  T K Bakshi; M K F Choo; C C Edwards; A G Scott; H H Hart; G P Armstrong
Journal:  Intern Med J       Date:  2002-11       Impact factor: 2.048

10.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis
Journal:  Circulation       Date:  2012-08-24       Impact factor: 29.690

View more
  2 in total

1.  False Positive Troponin I Rendering Two Admissions for "Recurrent Acute Myopericarditis".

Authors:  Rita Marinheiro; Pedro Amador; Leonor Parreira; Quitéria Rato; Rui Caria
Journal:  Open Cardiovasc Med J       Date:  2018-06-29

2.  Systemic and Cardiac Alterations After Long Bone Fracture.

Authors:  Birte Weber; Ina Lackner; Deborah Knecht; Christian Karl Braun; Florian Gebhard; Markus Huber-Lang; Frank Hildebrand; Klemens Horst; Hans-Christoph Pape; Anita Ignatius; Hubert Schrezenmeier; Melanie Haffner-Luntzer; Miriam Kalbitz
Journal:  Shock       Date:  2020-12       Impact factor: 3.533

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.